EMD Millipore Acquires Rights to Singulex's Life Science Research Business | GenomeWeb

NEW YORK (GenomeWeb) – Singulex announced today that it has signed an agreement giving EMD Millipore, a unit of Germany's Merck KGaA, the rights to control and manage its life science research business, which includes the company's single-molecule counting (SMC) technology.

The SMC technology enables the detection of single molecules such as proteins and metabolites in complex biological samples. It is the basis for Singulex's research-use-only Erenna instrument, which can detect single molecules down to the femtogram level.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.